Zenas BioPharma, Inc. (ZBIO) Stock Statistics & Valuation Metrics

Zenas BioPharma, Inc. has a market cap or net worth of $1.25B. The enterprise value is $938.90M.

Zenas BioPharma, Inc. has 53,679,165 shares outstanding. The number of shares has decreased by -2.65% in one year.

Zenas BioPharma, Inc.’s return on equity (ROE) is -1.56 and return on invested capital (ROIC) is -65.61%.

The current PE Ratio of Zenas BioPharma, Inc. is ―. Zenas BioPharma, Inc.’s PEG ratio is -0.03.

In the last 12 months, Zenas BioPharma, Inc. had revenue of 10.00M and earned -377.74M in profits. Earnings per share was -8.44.

In the last 12 months, operating cash flow was -172.33M and capital expenditures -18.00K, giving a free cash flow of -172.35M billion.

Zenas BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Zenas BioPharma, Inc. upcoming earnings date is May 14, 2026, Before Open (Confirmed).

Zenas BioPharma, Inc. as a current ratio of 5.61, with Debt / Equity ratio of 0.55%

In the past 12 months, Zenas BioPharma, Inc. has paid -79.00K in taxes.

Zenas BioPharma, Inc. EV to EBITDA ratio is -3.95, with an EV/FCF ratio of -8.79.

Zenas BioPharma, Inc. has $343.19M in cash and marketable securities with $1.33M in debt, giving a net cash position of $341.87M billion.

Gross margin is -380.37%, with operating margin of -2113.85%, and net profit margin of -3777.37%.

The average price target for Zenas BioPharma, Inc. is $43.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy